Validation-Based Insertional Mutagenesis (VBIM), A Powerful Forward Genetic Screening Strategy.
cell libraries
drug resistance
forward genetics
in vivo screens
insertional mutagenesis
lentiviral vectors
Journal
Current protocols
ISSN: 2691-1299
Titre abrégé: Curr Protoc
Pays: United States
ID NLM: 101773894
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
entrez:
22
3
2022
pubmed:
23
3
2022
medline:
25
3
2022
Statut:
ppublish
Résumé
Forward genetics begins with a biological phenotype and attempts to identify genetic changes that influence that phenotype. These changes can be induced in a selected group of genes, for instance, by using libraries of cDNAs, shRNAs, CRISPR guide RNAs, or genetic suppressor elements (GSEs), or randomly throughout the genome using chemical or insertional mutagens, with each approach creating distinct genetic changes. The Validation-Based Insertional Mutagenesis (VBIM) strategy utilizes modified lentiviruses as insertional mutagens, placing strong promoters throughout the genome. Generating libraries with millions of cells carrying one or a few VBIM promoter insertions is straightforward, allowing selection of cells in which overexpression of VBIM-driven RNAs or proteins promote the phenotype of interest. VBIM-driven RNAs may encode full-length proteins, truncated proteins (which may have wild-type, constitutive, or dominant-negative activity), or antisense RNAs that can disrupt gene expression. The diversity in VBIM-driven changes allows for the identification of both gain-of-function and loss-of-function mutations in a single screen. Additionally, VBIM can target any genomic locus, regardless of whether it is expressed in the cells under study or known to have a biological function, allowing for true whole-genome screens without the complication and cost of constructing, maintaining, and delivering a comprehensive library. Here, we review the VBIM strategy and discuss examples in which VBIM has been successfully used in diverse screens to identify novel genes or novel functions for known genes. In addition, we discuss considerations for transitioning the VBIM strategy to in vivo screens. We hope that other laboratories will be encouraged to use the VBIM strategy to identify genes that influence their phenotypes of interest. © 2022 Wiley Periodicals LLC.
Identifiants
pubmed: 35316583
doi: 10.1002/cpz1.394
pmc: PMC8969887
mid: NIHMS1781252
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e394Subventions
Organisme : NIH HHS
ID : W81XWH-18-1-0552
Pays : United States
Organisme : NIH HHS
ID : R01CA252224
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA252224
Pays : United States
Organisme : NIH HHS
ID : P01CA062220
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA062220
Pays : United States
Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Cancer Discov. 2020 Feb;10(2):270-287
pubmed: 31744829
Angiogenesis. 2008;11(1):101-6
pubmed: 18283548
Mol Cancer Res. 2014 Aug;12(8):1156-65
pubmed: 24736947
Proc Natl Acad Sci U S A. 2014 Aug 12;111(32):11721-6
pubmed: 25071181
J Clin Invest. 2012 Sep;122(9):3197-210
pubmed: 22886302
Nat Genet. 2015 Mar;47(3):199-208
pubmed: 25599403
Science. 2003 Jun 13;300(5626):1749-51
pubmed: 12805549
N Engl J Med. 2017 Dec 7;377(23):2287-2289
pubmed: 29211674
Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):46-51
pubmed: 20080798
Life Sci Alliance. 2020 Feb 18;3(4):
pubmed: 32071280
Cell. 2017 Feb 9;168(4):707-723
pubmed: 28187290
Sci Rep. 2017 Apr 4;7(1):641
pubmed: 28377632
Oncotarget. 2016 Aug 9;7(32):52597-52612
pubmed: 27221039
Radiother Oncol. 2014 Feb;110(2):348-54
pubmed: 24412016
Nat Commun. 2014 Dec 23;5:5871
pubmed: 25532760
Proc Natl Acad Sci U S A. 2021 Nov 23;118(47):
pubmed: 34795058
Genome Res. 2007 Aug;17(8):1186-94
pubmed: 17545577
Proc Natl Acad Sci U S A. 2020 Jun 30;117(26):15047-15054
pubmed: 32532922
Biochem Biophys Res Commun. 2013 Aug 2;437(3):452-6
pubmed: 23831628
Breast Cancer Res Treat. 2012 Feb;131(3):849-58
pubmed: 21479552
PLoS One. 2014 Nov 26;9(11):e112632
pubmed: 25426949
Nat Rev Mol Cell Biol. 2009 Oct;10(10):682-96
pubmed: 19773780
Cell. 2019 Aug 22;178(5):1189-1204.e23
pubmed: 31442407
Nature. 2017 Jul 27;547(7664):413-418
pubmed: 28723893
Mol Cancer. 2019 Mar 30;18(1):69
pubmed: 30927928
Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16339-44
pubmed: 19805303
Nat Commun. 2014 Dec 15;5:5712
pubmed: 25502142
Proc Natl Acad Sci U S A. 2011 May 10;108(19):7968-73
pubmed: 21518868
J Clin Oncol. 2008 Jan 1;26(1):44-53
pubmed: 18165639
Curr Med Chem. 2015;22(2):264-89
pubmed: 25386819
Cancer Res. 2009 Oct 15;69(20):8035-42
pubmed: 19789344
Biomol Concepts. 2013 Dec;4(6):567-82
pubmed: 25436757
Oncotarget. 2013 May;4(5):729-38
pubmed: 23676467
N Engl J Med. 2021 Sep 23;385(13):1241-1243
pubmed: 34551235